TEVA Analyst Ratings
Teva Pharmaceutical Industries Limited (TEVA) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry, with a market capitalization near $48.04B, listed on NYSE, employing roughly 32,008 people, carrying a beta of 0.82 to the broader market. Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. Led by Richard D. Francis, public since 1982-02-16.
Analyst Ratings
In the October 2026 monthly count, 12 analysts rated TEVA: 4 Strong Buy, 7 Buy, 1 Hold, 0 Sell and 0 Strong Sell.
Twelve months earlier, in October 2025: 12 analysts, 3 Strong Buy, 8 Buy, 1 Hold, 0 Sell and 0 Strong Sell.
Price Targets
- Average Target
- $45.80
- Median Target
- $45.00
- High
- $50.00
- Low
- $42.00
- Targets Published, Last 12 Months
- 19
Recent Price Targets
The 5 most recent of 18 price targets published in the last 12 months.
| Date | Firm | Analyst | Target | Price When Posted |
|---|---|---|---|---|
| Sep 23, 2026 | Oppenheimer | Les Sulewski | $50.00 | $39.52 |
| Sep 9, 2026 | Leerink Partners | Not named | $45.00 | $36.76 |
| Sep 4, 2026 | UBS | Ashwani Verma | $48.00 | $36.62 |
| Aug 12, 2026 | Barclays | Not named | $42.00 | $36.48 |
| Jul 28, 2026 | Piper Sandler | David Amsellem | $44.00 | $31.08 |
Recent Upgrades & Downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 4, 2026 | UBS | maintain | Buy | Buy |
| Aug 12, 2026 | Barclays | maintain | Overweight | Overweight |
| Jul 28, 2026 | Piper Sandler | maintain | Overweight | Overweight |
| May 6, 2026 | Barclays | maintain | Overweight | Overweight |
| Apr 30, 2026 | UBS | maintain | Buy | Buy |
Quantitative Rating
TEVA carries a model grade of B- (overall score 2 of 5), computed from six valuation and financial measures (discounted cash flow, return on equity, return on assets, debt to equity, price to earnings and price to book), each scored 1 to 5. It is not an analyst rating.
How to Read TEVA Analyst Coverage
Sell-side equity analysts publish three primary outputs: ratings (Strong Buy / Buy / Hold / Sell / Strong Sell, or firm-specific equivalents), price targets, and EPS / revenue estimate revisions. Rating consensus moves slowly relative to price; it reflects 12-month directional conviction rather than near-term momentum. Price targets are more responsive but typically drift behind realized price during sharp moves. The most actionable signal for options traders is a cluster of ratings actions across multiple firms within a short window, which compresses or expands implied volatility on a horizon of days to weeks and shifts the put-call skew toward the directional consensus. The recent-actions table above shows the five most recent firm-level changes; longer histories live behind aggregator sources.
For event-driven options sizing, pair the consensus rating and target distribution with the implied-volatility surface and dealer-positioning view. Aggressive target hikes from multiple firms tend to tighten put skew (downside protection becomes relatively cheaper); aggressive cuts widen put skew. The size of the IV response in the hours after a rating change is visible on the per-ticker volatility skew page and the gamma-exposure page, both of which show how dealer hedging propagates the analyst-driven flow into the listed options chain.
Learn how analyst ratings is reported and how to read the data →
Frequently asked TEVA analyst ratings questions
- What is the TEVA consensus price target?
- As of the latest aggregator update, Teva Pharmaceutical Industries Limited (TEVA) carries a consensus 12-month price target of $45.80. Target ranges run from a low of $42.00 to a high of $50.00. The target is the average of the price targets published by sell-side equity analysts covering the name.
- What is the analyst rating consensus on TEVA?
- In the October 2026 monthly count, 12 analysts rated TEVA, and the distribution tilts to the Buy side: 4 Strong Buy, 7 Buy, 1 Hold, 0 Sell and 0 Strong Sell. Rating consensus moves slowly relative to price; it reflects sell-side conviction over a 12-month horizon rather than near-term momentum.
- What recent ratings actions has TEVA seen?
- The five most recent ratings actions on TEVA appear on the page above. Sell-side rating changes are watched for two reasons: an upgrade or downgrade with a meaningful target revision moves the consensus and can trigger short-term positioning shifts, and the firm-level rating cluster (multiple firms moving in the same direction within a short window) is a clearer signal than any single action. Options markets often price the implied-vol response within minutes of the announcement.
- How do analyst targets affect TEVA options pricing?
- Analyst target revisions tend to be priced in by the lit options market within minutes of publication, but persistent target drift over weeks does correlate with implied-volatility movement. Aggressive target hikes from multiple firms inside a single quarter tighten put skew (downside protection becomes cheaper relative to upside speculation); aggressive cuts widen put skew. The most actionable read is the implied-vol response in the hours after a target change, which is visible on the per-ticker volatility skew page.